Prior to founding Insignis Therapeutics, Mingbao started 3RServices LLC, a drug development CRO serving the biotech/pharmaceutical industry since 2013. He has over 25 years of hands on drug development experience previously having worked at Bayer, Marinus Pharmaceuticals and Honeywell among others. He is a co-inventor of ZTALMY® (ganaxolone oral suspension 50 mg/mL) approved for CDKL5 deficiency disorder (CDD) in children and young adults.

Having intimately involved in the clinical development and regulatory process of ZTALMY® and multiple drug candidates through late-stage clinical trials, Mingbao has gained critical knowledge and experience required to move a drug from the lab through the development process to reach regulatory approval. Having managed a highly profitable drug development CRO for over a decade, Mingbao has demonstrated business and management skills to accomplish more with less.

Mingbao holds a PhD in organic chemistry from the University of Illinois, Urbana-Champaign and an Executive MBA from University of New Haven. He is an inventor or co-inventor of over 25 issued patents and patent applications. He has authored or co-authored over 18 peer-reviewed publications. He is a recipient of numerous awards including the 2001 Bayer Science and Technology Award, the highest award for scientific achievement at Bayer Research.

Prior to joining Insignis, Ray was Executive Director, Drug Development at Marinus Pharmaceuticals. Ray is an experienced pharmaceutical industry scientist, with expertise in chemistry and drug development. Ray has most recently led the process chemistry and development of Ganaxalone, a neurosteroid for treatment of epilepsy, at Marinus Pharmaceuticals, where it was recently FDA approved. Previously he spent over 20 years at Pfizer Central Research, followed by a tenure at Purdue Pharma in development of novel, non-addictive pain therapies. He has strong regulatory experience with API process development.

Ray holds a Ph.D. in Organic Chemistry from the University of Michigan.

Bette is a highly accomplished professional with over 25 years of pharmaceutical industry experience supporting the development of novel therapeutical agents. Her background includes strategic planning, project/laboratory management, reference standard management, quality systems design, method development, formulation development, validation (analytical/process), stability determination, regulatory strategy and submissions preparation for drug substances and a variety of products including parenteral, inhalable, oral solid and liquid dosage forms with 4 approved NDAs and 2 MAAs. Through her career, she has supported all phases of drug development from preclinical through commercial. Some of the companies that Bette has worked for include Marinus Pharmaceuticals, Asklepion Pharmaceuticals, ViroPharma (now Takeda), Cephalon Incorporated (Although now Teva) and Magellan Laboratories (now Catalent).

She has developed novel analytical methods with the required sensitivity, precision and accuracy to support the intended use of the method. Methods were designed with the input of the user to ensure they could separate process issues from analytical short-comings. Then, using the analytical data, Bette has worked with CDMOs to optimize the formulation itself. She has overseen the GMP readiness of the manufacturing suite, participating in the design of environmental monitoring and cleaning programs, and prepared batch records. Bette has extensive experience is leading investigations and driving them to closure. Bette’s strong negotiation and mentoring skills have allowed her to manage the needs of her projects with those of vendor, resulting in strong vendor partnerships. She has successfully help senior management understand the criticality of vendor relationships to the company success.

Bette holds a PhD in Pharmaceutical Chemistry and Pharmaceutical Analysis from University of Kansas. She is a co-author of numerous peer-reviewed publications.

Prior to founding Insignis Therapeutics, Mingbao started 3RServices LLC, a drug development CRO serving the biotech/pharmaceutical industry since 2013. He has over 25 years of hands on drug development experience previously having worked at Bayer, Marinus Pharmaceuticals and Honeywell among others. He is a co-inventor of ZTALMY® (ganaxolone oral suspension 50 mg/mL) approved for CDKL5 deficiency disorder (CDD) in children and young adults.

Having intimately involved in the clinical development and regulatory process of ZTALMY® and multiple drug candidates through late-stage clinical trials, Mingbao has gained critical knowledge and experience required to move a drug from the lab through the development process to reach regulatory approval. Having managed a highly profitable drug development CRO for over a decade, Mingbao has demonstrated business and management skills to accomplish more with less.

Mingbao holds a PhD in organic chemistry from the University of Illinois, Urbana-Champaign and an Executive MBA from University of New Haven. He is an inventor or co-inventor of over 25 issued patents and patent applications. He has authored or co-authored over 18 peer-reviewed publications. He is a recipient of numerous awards including the 2001 Bayer Science and Technology Award, the highest award for scientific achievement at Bayer Research.

Jun is the co-founder and CEO of Pharmacin, a drug development company headquartered in Shenzhen, China. Jun has over 15 years of experience in major international pharmaceutical companies including Novartis and Boehringer Ingelheim in drug discovery and development. She has worked on multiple new drug targets, including target proposals, target validation and assay development for new drug candidates in Immunology and cardiovascular disease areas.

Jun also worked in drug development focusing on metabolism, anaerobic gut flora systems and drug-drug interactions studies. Overall, she has been involved in the discovery of a dozen drug candidates and development of several new drugs.

Jun’s diverse experience in institutional management has helped her build up an extensive network in the pharmaceutical industry, government, and university communities both in China and the United States.

Jun holds a BS degree from Nanjing University, and a MS degree from SUNY Buffalo.

Clarence Kwan, CAIA, CPA, has over 40 years of financial advisory and management experience in the U.S., China and Eastern Europe. Since the mid-1980’s, he has been advising U.S., Chinese, and other global companies on cross border investments, including mergers & acquisitions, joint ventures, and alternative investments. Since retirement from Deloitte in 2012, he has served on the boards of various for-profit and non-profit organizations, including East West Bank, Smartlink Health Solutions, SupChina, Piermont Bank, and the Committee of 100.

During his 34 years with Deloitte, Clarence held a number of national and international leadership roles, including serving as the National Managing Partner of the U.S. Chinese Services Group, Deputy CEO of Deloitte China, and a founding partner of Deloitte Czech Republic. In addition to being a trusted advisor to clients, Clarence is well recognized for his leadership in building two of Deloitte’s most important emerging market practices, Eastern Europe and China. In Prague during the early 90’s, he was instrumental in developing the financial advisory, audit, and consulting capabilities of the Czech practice and helped expand its headcount from about 30 people to 250 people in three years. Based in Beijing from 1995 to 2002, he grew Deloitte’s China operations from about 100 people to over 1,000, and expanded service capabilities to include management consulting and financial advisory services.

Clarence was born and raised in Hong Kong and is fluent in Mandarin, Cantonese and English. He graduated from the University of Texas at Austin with a B.A. degree in psychology and a master’s degree in professional accounting in 1978. He is a Certified Public Accountant and a Certified Alternative Investment Analyst.